Deka Biosciences: $20 Million Secured To Maximize Patient Benefits Through Improved Pharmacokinetics
By Annie Baker ● Oct 9, 2023
Biotech company Deka Biosciences recently announced that it has successfully closed a $20 million Series B2 financing with a syndicate of life science investors led by MPM BioImpact and joined by additional investors, including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.